SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is a major trending topic as its Q4 earnings, which beat expectations, were met with a significant stock dip, fueling intense debate among investors. The community is sharply divided, with many viewing the sharp decline as a prime 'buy the dip' opportunity for a long-term hold, citing strong fundamentals. Conversely, bears are expressing concerns over cautious guidance, the implications of its Warner Bros. Discovery acquisition, increased content spending, and the pausing of share buybacks.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is trending as escalating geopolitical tensions, including President Trump's tariff threats against European nations over Greenland, and growing concerns about US dollar stability drive investors to seek safe havens. The community is actively discussing gold's role as a premier hard asset amidst broad market uncertainty, anticipating further appreciation as capital potentially rotates from equities and traditional bonds.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is a hot topic as the community anticipates significant announcements, fueled by recent industry awards and confirmation of continued work with Celestial AI, now part of Marvell. Discussion centers on POET's patented optical interposer technology, seen as a crucial solution for the escalating demand for high-speed, power-efficient optical interconnects in AI data centers. Many believe the company is poised for major customer orders, positioning it as a key player in the ongoing optical supercycle.

America's Oil Reserve for the Digital Age

U.S Oil

USOR CRYPTO is experiencing a highly polarized trend following a rapid price surge, sparking intense community debate. While many celebrate substantial gains and anticipate further rallies, a vocal segment warns of a potential "rug pull" or pump-and-dump, cautioning investors due to its meme coin characteristics. Amidst this volatility, new participants are actively seeking information on how to acquire the token.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

DIA is trending amid active discussions surrounding renewed tariff threats related to the Greenland acquisition proposal, which is raising fears of broader trade conflicts. The community is sharply divided, with many anticipating a significant market correction, while others see current pullbacks as buying opportunities, hoping for a swift market rebound or a favorable Supreme Court ruling on tariffs. This situation highlights ongoing concerns about global trade stability and US foreign policy implications.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust (SPY) is actively trending amid heightened geopolitical rhetoric, particularly surrounding discussions of a potential U.S. acquisition of Greenland and associated tariff implications. The community is sharply divided, with many anticipating a significant rebound from a recent market dip, while others express concerns about escalating global tensions and upcoming public statements from a prominent political figure. Broader market sentiment is currently influenced by a tug-of-war between 'buy the dip' enthusiasm and fears of further instability affecting international asset holdings.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending amidst escalating geopolitical trade tensions and recent service outages, which have contributed to a broader tech sell-off and driven its daily RSI to historically oversold levels. The community is sharply divided between those advocating to "buy the dip" ahead of anticipated strong earnings and others who question its long-term growth trajectory under current market pressures.

What is DAG? In more traditional blockchains, the host provides the food/drinks (i.e resources) for this party. And when the guests arrive, the amount of resources can only accommodate so many people, the portions are small and then everything eventually runs out and the party ends. Think Constellation DAG like a potluck (a party where everyone brings food/drinks). With every added guest (node to the network), the more resources the party has to keep going. This is the nature of Constellation, a distributed system that scales horizontally.  Is Constellation a Blockchain? Not exactly. Although inspired by the principles of decentralization, many standard blockchains such as Bitcoin and Ethereum face scalability issues. This is why the next, generation of decentralized networks such as Hashgraph, IOTA, and Constellation have turned to DAG.  What is a Microservice? “Microservices” is an approach to application development in which a large application is built as a suite of modular services. Each module supports a specific business goal and uses a simple, well-defined interface to communicate with other sets of services. Uber, for example, is not a singular app purse. It is a unified app which means it is a single interface that brings together their driver app, their rider app, and their corporate team app.

Constellation

Constellation is trending due to its recent listing on Kraken and increased accessibility via the Base network, alongside new partnerships including a Web3 National Lottery integration in the Philippines. The community is keenly focused on Constellation's strategic shift towards enterprise and government use cases, like its long-standing DoD contracts and recent MiCAR compliance, highlighting its Layer 0 Hypergraph architecture for secure data solutions in the AI era.

CACI International, Inc. is a holding company, which engages in the provision of information solutions and services in support of national security missions and government transformation for intelligence, defense, and federal civilian customers. It operates through the Domestic Operations and International Operations segments. The Domestic Operations segment offers information solutions and services to U.S. federal government agencies, state and local governments, and commercial enterprises to different market areas, including business systems, command and control, communications, cyber security, enterprise information technology, health, intelligence services, investigation and litigation support, logistics and material readiness, and surveillance and reconnaissance. The International Operations segment includes the provision of IT services and proprietary data and software products, serving commercial and government customers. The company was founded by Herb Karr and Harry Markowitz in July 1962 and is headquartered in Reston, VA.

Caci International Inc. - Registered Shares - Class A

CACI International is trending following recent strategic acquisitions and significant contract wins across critical national security, space, and defense technology sectors, further bolstered by a substantial share repurchase program. The community is notably bullish, highlighting the company's robust position in government-mandated areas like AI and cybersecurity, often seen as a resilient investment despite broader defense spending discussions.

The Kraft Heinz Co. engages in the manufacture and market of food and beverage products. It operates through the North America and International geographical segments. The company was founded on July 2, 2015, and is headquartered in Pittsburgh, PA.

Kraft Heinz Co

Kraft Heinz is actively discussed amid its upcoming separation into two independent companies and the appointment of a new CEO, with many anticipating this will unlock significant value. Community sentiment is polarized between those who see current price levels as a rare buying opportunity and those concerned about it being a "value trap," often fueled by claims of market manipulation and recent analyst downgrades.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NRx Pharmaceuticals (NASDAQ:NRXP) Given "Buy" Rating at BTIG Research

BTIG Research reaffirmed a "buy" rating and set a $25.00 price target on shares of NRx Pharmaceuticals in a research note on Thursday...

<ul class="summary-bullets"><li>The move is a major step toward FDA approval of NRX-100, its investigational drug.</li><li>Currently, no FDA-approved medications exist specifically to treat suicidal thoughts, with electroshock therapy remaining the only sanctioned option.</li><li>Earlier, Osmind presented data from a 20,000-patient subset at the 2024 American Society of Clinical Psychopharmacology meeting.</li></ul>NRx Pharmaceuticals, Inc. (NRXP) on Wednesday announced that it has licensed Real World Evidence (RWE) from more than 70,000 U.S. patients who received either intravenous ketamine or nasal S-ketamine as part of their treatment.The move is a major step toward FDA approval of its investigational drug, NRX-100 (preservative-free ketamine), aimed at treating suicidal ideation in patients with depression and suicidal tendencies.&nbsp;<h2 class="st-heading-2">Collaboration With Osmind</h2>The RWE data comes from Osmind, a neuropsychiatry technology platform used across U.S. clinics, providing detailed, regulatory-grade patient records. This joint effort allows NRx to submit a comprehensive dataset to the FDA in support of Accelerated Approval for NRX-100 under its Fast Track Designation.&nbsp;The approach could mark a breakthrough, as currently no FDA-approved medications exist specifically to treat suicidal thoughts, with electroshock therapy remaining the only sanctioned option.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/NRXP">NRx Pharmaceuticals' stock&nbsp;</a>traded over 21% higher in Wednesday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock jumped to ‘bullish’ territory from ‘bearish’ the previous day. Message volume shifted to ‘high’ from ‘normal’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">Preliminary Findings And Expectations</h2>Earlier, Osmind presented data from a 20,000-patient subset at the 2024 American Society of Clinical Psychopharmacology meeting. Results suggested rapid improvement in depression and suicidal ideation with intravenous ketamine.&nbsp;NRx anticipates that analysis of the full 70,000-patient dataset will provide even stronger evidence to support the FDA submission.<blockquote>“An American commits suicide every 11 minutes and ketamine has become widely used off label as a drug that has been seen to reduce suicidal ideation in clinical trials.”-Jonathan Javitt, Chairman and CEO, NRx Pharmaceuticals</blockquote>NRXP stock has declined by over 58% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-nrxp-stock-surge-pre-market-today/cmULXc2R4eL">Why Did NRXP Stock Surge 21% Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a hand holding a medical syringe seen displayed in front of the NRx Pharmaceuticals logo.

Why Did NRXP Stock Surge 21% Pre-Market Today?

The company is using a large US real-world evidence dataset to support its accelerated FDA approval for its ketamine-based drug.

Equity

The company is using a large US real-world evidence dataset to support its accelerated FDA approval for its ketamine-based drug.


D. Boral Capital Reaffirms "Buy" Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

D. Boral Capital restated a "buy" rating and issued a $34.00 target price on shares of NRx Pharmaceuticals in a research report on Monday...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Consensus Recommendation of "Moderate Buy" from Analysts

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six research firms that are covering the firm, MarketBeat Ratings reports...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Short Interest Up 38.2% in December

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Get Free Report) saw a large growth in short interest in the month of December. As of December 15th, there was short interest totaling 1,744,957 shares, a...

NRx Pharmaceuticals (NASDAQ:NRXP) Given Buy Rating at HC Wainwright

HC Wainwright reiterated a "buy" rating and set a $40.00 target price on shares of NRx Pharmaceuticals in a research note on Tuesday...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Average Rating of "Moderate Buy" from Analysts

Shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Get Free Report) have received an average recommendation of "Moderate Buy" from the six brokerages that are presently covering the firm, Marketbeat...

BTIG Research Reiterates Buy Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

BTIG Research reaffirmed a "buy" rating and set a $25.00 price objective on shares of NRx Pharmaceuticals in a research report on Wednesday...

What is HC Wainwright's Forecast for NRXP FY2025 Earnings?

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Free Report) - Equities researchers at HC Wainwright cut their FY2025 earnings per share estimates for shares of NRx Pharmaceuticals in a report issued on...

NRx Pharmaceuticals (NASDAQ:NRXP) Upgraded at Wall Street Zen

Wall Street Zen raised NRx Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Sunday...

NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded by Jonathan C. Javitt on September 18, 2017 and is headquartered in Wilmington, DE.

NRX Pharmaceuticals Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$0.01	--	--	N/A
Q3 '25	-$0.13	-$0.27	-107.69%	MISSED
Q2 '25	-$0.15	-$0.98	-552.68%	MISSED
Q1 '25	-$0.28	-$0.34	-20.00%	MISSED
Q4 '24	-$0.37	-$0.35	3.18%	BEAT

NRXP
NRX Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest NRXP News

NRXPNRX Pharmaceuticals Inc